Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506ACS MEDICINAL CHEMISTRY LETTERSIF42023-10-052OA
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy ApplicationsPHARMACEUTICALSIF4.82022-02-012OAAI
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3PHARMACEUTICALSIF4.82021-11-267OAAI
Inhibition of the Cytolytic Protein Perforin Prevents Rejection of Transplanted Bone Marrow Stem Cells in Vivo抑制细胞溶解蛋白穿孔素可防止体内移植骨髓干细胞的排斥反应JOURNAL OF MEDICINAL CHEMISTRYIF6.82019-09-188PREAI
Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancersCANCER RESEARCHIF16.62019-07-014PRE
Hypoxic cell killing by SN36506, a novel hypoxia-activated prodrugRADIOTHERAPY AND ONCOLOGYIF5.32017-05-010OAAI
Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapyBIOCHEMICAL PHARMACOLOGYIF5.62016-09-0117PREAI
DTP-006: a novel, orally bioavailable hypoxia-activated prodrugRADIOTHERAPY AND ONCOLOGYIF5.32016-04-010OAAI
The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trialCANCER RESEARCHIF16.62015-08-016PRE
Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein PerforinJOURNAL OF MEDICINAL CHEMISTRYIF6.82013-11-1929OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向